Related Experiment Video
Updated: Oct 10, 2026

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
Published on: April 15, 2014
Cochlear Implantation in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Jacob Mabey1, Hannah Dunn1, Justin Cottrell1
1Department of Surgery, Division of Otolaryngology-Head and Neck Surgery Yale School of Medicine New Haven Connecticut USA.
Abstract:
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a neuroimmunologic demyelinating disorder that may present with central or peripheral sensorineural hearing loss (SNHL). This case describes a 43-year-old female with MOGAD and profound right-sided SNHL who did not improve with neuroimmunologic therapy. Additional immunologic and radiographic workup was unrevealing. The patient underwent right cochlear implantation (CI) without complication and with significant improvement in her speech recognition. Despite the possibility of central SNHL, select patients with MOGAD may benefit from CI, and thus MOGAD should not be considered an absolute contraindication to cochlear implantation.
